Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other financing activities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other financing activities for 6 consecutive years, with $102000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities rose 54.55% to $102000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $624000.0, a 845.45% increase, with the full-year FY2025 number at $624000.0, up 845.45% from a year prior.
  • Other financing activities was $102000.0 for Q4 2025 at Cartesian Therapeutics, up from $43000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $454000.0 in Q1 2025 to a low of $25000.0 in Q2 2025.
  • A 3-year average of $133333.3 and a median of $84000.0 in 2024 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 54.55% in 2025; the steepest drop was 54.55% in 2025.
  • Cartesian Therapeutics' Other financing activities stood at $110000.0 in 2022, then crashed by 40.0% to $66000.0 in 2024, then surged by 54.55% to $102000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Other financing activities are $102000.0 (Q4 2025), $43000.0 (Q3 2025), and $25000.0 (Q2 2025).